Targeting ferroptosis in breast cancer

Biomarker Research

Dengdi Hu¹  Wenying Zhuo¹  Yongxia Chen²  Yulu Zhou²  Ling Xu²  Lini Chen²  Cong Chen²  Linbo Wang²  Jingjing Yang²  Misha Mao²  Jichun Zhou²  Xun Zhang²  Zhaoqing Li³ 

[1] Cixi People’s Hospital Medical and Health Group, 315300, Ningbo, Zhejiang, China;Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310000, Hangzhou, Zhejiang, China;Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, 310000, Hangzhou, Zhejiang, China;Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310000, Hangzhou, Zhejiang, China;Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, Zhejiang, China;Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, 310000, Hangzhou, Zhejiang, China;

关键词: Ferroptosis;    Breast cancer;    Regulated cell death;    Crosstalk;    Ferroptotic regulators;    Historical perspective;   

DOI  :  10.1186/s40364-020-00230-3

来源: Springer

【 摘 要 】

Ferroptosis is a recently discovered distinct type of regulated cell death caused by the accumulation of lipid-based ROS. Metabolism and expression of specific genes affect the occurrence of ferroptosis, making it a promising therapeutic target to manage cancer. Here, we describe the current status of ferroptosis studies in breast cancer and trace the key regulators of ferroptosis back to previous studies. We also compare ferroptosis to common regulated cell death patterns and discuss the sensitivity to ferroptosis in different subtypes of breast cancer. We propose that viewing ferroptosis-related studies from a historical angle will accelerate the development of ferroptosis-based biomarkers and therapeutic strategies in breast cancer.

【 授权许可】

CC BY